KRAS G12C is the hot new play in cancer R&D, and Novartis jumps in with a combo deal
These days in the frenzied cancer R&D field, every step forward with a monotherapy is almost immediately followed by a combo approach. And we’re seeing that again today.
A little more than a month since Amgen whipped up some excitement for its KRAS G12C program with a positive early snapshot of human data at ASCO, Novartis is stepping into the arena — adding a partnership that puts them in the race with a combination that will likely get plenty of added attention in the clinic.
Basic subscription required
Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.